ENDROLIN

Contents
Leuprolide acetate
Indications
Treatment of prostate cancer w/ metastases, endometriosis at genital & extragenital localization.
Dosage
Prostate cancer 1 SC inj renewed every 4 wk. Endometriosis Start treatment during the 1st 5 days of the menstrual cycle. 1 SC or IM inj renewed every 4 wk. Max duration: 6 mth.
Contraindications
Vag bleeding of undetermined origin, pregnancy, lactation.
Special Precautions
Women w/ known risk factors for decreased bone mineral content.
Adverse Drug Reactions
Hypoestrogenism in females & hypotestosteronism in males. Hot flushes, blurred vision, decreased libido, dizziness, edema, headache, nausea, vomiting, breast tenderness, wt gain, cardiac arrhythmias, insomnia, anaphylaxis, paresthesia, syncope.
View ADR Monitoring Form
Pregnancy Category (US FDA)



Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.
MIMS Class
Hormonal Chemotherapy / Trophic Hormones & Related Synthetic Drugs
ATC Classification
L02AE02 - Leuprorelin ; Belongs to the class of gonadotropin releasing hormone analogues. Used in endocrine therapy.
Drug Classification
G
Presentation/Packing
Form Packing/Price Photo
Endrolin vial
Endrolin 3.75 mg x 1's (Rp1045000)